[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561164":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":16,"responsibleParty":97,"collaborators":10,"id":99,"slug":10,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":10,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":10},"Operable metastatic melanoma",null,[12],{"name":13,"role":14,"phone":10,"phoneExt":10,"email":15},"Charlée NARDIN, MD PhD","CONTACT","cnardin@chu-besancon.fr",[17,28,41,49,57,65,73,81,89],{"facility":18,"status":19,"city":20,"state":10,"zip":10,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":10},"CHU Angers","ACTIVE_NOT_RECRUITING","Angers","France",{"type":23,"coordinates":24},"Point",[25,26],-0.55202,47.47156,{"lat":26,"lon":25},{"facility":29,"status":30,"city":31,"state":10,"zip":10,"country":21,"cosmosGeoPoint":32,"geoPoint":36,"contacts":37},"CHU de Besançon","RECRUITING","Besançon",{"type":23,"coordinates":33},[34,35],6.01815,47.24878,{"lat":35,"lon":34},[38,39],{"name":13,"role":14,"phone":10,"phoneExt":10,"email":15},{"name":40,"role":14,"phone":10,"phoneExt":10,"email":10},"CHarlée NARDIN, MD PhD",{"facility":42,"status":19,"city":43,"state":10,"zip":10,"country":21,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"Hôpital Avicenne","Bobigny",{"type":23,"coordinates":45},[46,47],2.45012,48.90982,{"lat":47,"lon":46},{"facility":50,"status":19,"city":51,"state":10,"zip":10,"country":21,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"CH de Boulogne-sur-Mer","Boulogne-sur-Mer",{"type":23,"coordinates":53},[54,55],1.61373,50.72485,{"lat":55,"lon":54},{"facility":58,"status":19,"city":59,"state":10,"zip":10,"country":21,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"CHU Clermont-Ferrand","Clermont-Ferrand",{"type":23,"coordinates":61},[62,63],3.08682,45.77969,{"lat":63,"lon":62},{"facility":66,"status":19,"city":67,"state":10,"zip":10,"country":21,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"Centre de Lutte Contre le Cancer Léon Bérard","Lyon",{"type":23,"coordinates":69},[70,71],4.84789,45.74906,{"lat":71,"lon":70},{"facility":74,"status":19,"city":75,"state":10,"zip":10,"country":21,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"ICO René Gauducheau","Saint-Herblain",{"type":23,"coordinates":77},[78,79],-1.651,47.21154,{"lat":79,"lon":78},{"facility":82,"status":19,"city":83,"state":10,"zip":10,"country":21,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Institut Universitaire de Cancérologie de Toulouse","Toulouse",{"type":23,"coordinates":85},[86,87],1.44367,43.60426,{"lat":87,"lon":86},{"facility":90,"status":19,"city":91,"state":10,"zip":10,"country":21,"cosmosGeoPoint":92,"geoPoint":96,"contacts":10},"CH de Valence","Valence",{"type":23,"coordinates":93},[94,95],4.90956,44.9256,{"lat":95,"lon":94},{"type":98,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100561164",false,"NCT06586593","Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)","ETUDE NEOMEL: TRAITEMENT NEOADJUVANT PAR IMMUNOTHERAPIE DU MELANOME METASTATIQUE OPERABLE EN VIE REELLE (GCC)","NEOMEL","Inclusion Criteria:\n\n* Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \\[AJCC\\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\\'s refusal to be operated.\n* Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed\n\nExclusion Criteria:\n\n* Uveal melanoma","ALL","18 Years",{"count":109,"type":110},77,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.\n\nThe complete histological response will be assessed.",[114],"Melanoma Metastatic","2024-09-06",{"date":117,"type":118},"2024-09-19","ACTUAL",{"date":120,"type":118},"2023-03-24",{"date":122,"type":110},"2025-01",{"name":5,"class":6},9]